🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "huge turning point" in the fight against drug-resistant strains of the bacteria, according to scientists.

A Global Challenge

The sexually transmitted infection are increasing globally, with estimates suggesting in excess of 82 million infections annually. Notably increased rates are reported in the African continent and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune advancement in the context of rising global incidence, the spread of superbugs and the highly restricted therapeutic options at this time.”

Public health authorities are deeply concerned about the rise in antibiotic-resistant strains. The WHO has listed it as a "critical concern". Ongoing monitoring showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Gain Authorization

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in December for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers believe that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This medication, which is employed against urinary tract infections, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment emerged from a unique collaborative effort for drug creation. The charitable organization GARDP worked alongside the drug firm its industry partner to bring it to fruition.

“This approval represents a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Clinical Trial Results and Global Access

Based on findings detailed in a prominent scientific publication, the new drug eradicated more than 90% of uncomplicated infections. This establishes an equal footing with the typical regimen, which involves an injection and a pill. The study included over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the authority to register and commercialise the drug in many low-income and middle-income countries.

Clinicians on the front lines have voiced optimism. Having a easy-to-administer therapy of this kind is seen as a "revolutionary step" for gonorrhoea control. This is deemed essential to reduce the burden of the infection for people and to prevent the spread of extremely resistant gonorrhoea worldwide.